Eleusis Overview

  • Founded
  • 2013
  • Status
  • Private
  • Employees
  • 9
  • Latest Deal Type
  • Later Stage VC
  • (In Progress)
  • Latest Deal Amount
  • $12.5M
Latest Deal Amount
  • Investors
  • 4

Eleusis General Information


Developer of small molecule drugs intended to unlocking the potential of serotonin 2A receptor agonists. The company develops restricted small molecule drugs by unlocking the anti-inflammatory potential of psychedelics that transform psychiatry Eleusis, enabling the advance of therapeutics targeting urgent unmet needs across a broad spectrum of inflammatory and stress-related diseases.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Primary Office
  • 11 East 44th Street
  • Suite 704
  • New York, NY 10017
  • United States
+1 (646) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Eleusis Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Later Stage VC 08-Jul-2020 $12.5M 0000 In Progress Clinical Trials - General
4. Later Stage VC 0000 000.00 Completed Clinical Trials - General
3. Angel (individual) 27-Jun-2016 00.000 00.000 Completed Clinical Trials - General
2. Grant 01-Jul-2014 $16.1K $3.5M Completed Startup
1. Seed Round $3.5M $3.5M Completed Startup
To view Eleusis’s complete valuation and funding history, request access »

Eleusis Executive Team (4)

Name Title Board Seat Contact Info
Shlomi Raz Co-Founder, Chief Executive Officer, Chairman, President & Board Member
Berrak Kocaoglu Director, Corporate Development
Charles Nichols Co-Founder & Chairman of Scientific Advisory Board
Bryan Clifton MD Chief Medical Officer
To view Eleusis’s complete executive team members history, request access »

Eleusis Board Members (3)

Name Representing Role Since
Charles Nichols Eleusis Co-Founder & Chairman of Scientific Advisory Board 000 0000
David Guyer MD Self Board Member 000 0000
Patrick Vernon Self Board Member 000 0000
To view Eleusis’s complete board members history, request access »

Eleusis Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Eleusis Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
San Diego State University Research Foundation Limited Partner 000 0000 000000 0
Government of UK Government Minority 000 0000 000000 0
Noetic Psychedelic Fund Venture Capital Minority 000 0000 000000 0
Tom Rutledge Angel (individual) Minority 000 0000 000000 0
To view Eleusis’s complete investors history, request access »

Eleusis Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
0000000 00000000 0 14-Dec-2020 000000000000000000 Clinics/Outpatient Services 000000 000
To view Eleusis’s complete acquisitions history, request access »